Needham analyst Ami Fadia has maintained their neutral stance on MRUS stock, giving a Hold rating yesterday.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ami Fadia’s rating is based on the current data surrounding Merus’s petosemtamab treatment in colorectal cancer, which does not yet provide compelling evidence of strong clinical activity. The abstract data presented at the Triple meeting showed mixed results across different lines of treatment.
In the first-line treatment, although the combination with FOLFOX/FOLFIRI showed a high response rate, the sample size was too small to draw definitive conclusions. The second-line treatment results were slightly better than previous benchmarks, but again, the data is not mature enough to confirm these findings. Lastly, the monotherapy in the third-line treatment showed limited efficacy, indicating that more follow-up is necessary. These factors contribute to the Hold rating as further data is needed to assess the true potential of petosemtamab in colorectal cancer.
According to TipRanks, Fadia is a 5-star analyst with an average return of 11.8% and a 50.11% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Immuneering, Biogen, and Jazz Pharmaceuticals.